Guaco in 2026: what Anvisa recognizes, how to use it, and the key warnings
Anvisa’s monograph classifies guaco under traditional use, with specific preparations, doses, duration limits, and interactions that restrict broader claims.
Read articlePharmacopoeia & Phytotherapy
Monographs, regulation, SUS, Anvisa and official references on medicinal plants and herbal medicines.
4articles
Espinheira-santa: what the Brazilian Pharmacopoeia recognizes, official warnings, and what evidence cannot promise
Brazilian official sources recognize traditional use of espinheira-santa for relief of heartburn and dyspepsia, but that is not the same as curing gastritis, reflux disease, or ulc...
Read article
Brazil’s 2026 herbal-medicine rules: what changed in simplified registration and what registration alone does not prove
Anvisa’s new framework updated herbal-medicine registration, quality controls, and monographs. Here is what the simplified pathway establishes — and what it does not.
Read article
Brazilian Pharmacopoeia 8th edition: what changed for medicinal plants and what it does not prove about efficacy
The 8th edition updates medicinal-plant monographs and methods. Learn how to read the compendium without confusing quality control with clinical efficacy.
Read article